Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.60 |
| ▸ | BACE2 | Q9Y5Z0 | 13/20 | 0.60 |
| ▸ | CTSD | P07339 | 4/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144840 | 0.94 | BACE1 (0.62) | BACE1BACE2CTSDAPP | |
| SCHEMBL5146716 | 0.86 | BACE1 (0.59) | BACE1BACE2CTSDAPP | |
| SCHEMBL4706860 | 0.86 | BACE1 (0.61) | BACE1BACE2CTSDAPP | |
| SCHEMBL4706493 | 0.84 | BACE1 (0.63) | BACE1BACE2CTSDAPP | |
| SCHEMBL4707284 | 0.84 | BACE1 (0.65) | BACE1BACE2CTSDAPP | |
| SCHEMBL4706119 | 0.83 | BACE1 (0.67) | BACE1BACE2CTSDAPP | |
| SCHEMBL4707072 | 0.82 | BACE1 (0.63) | BACE1BACE2CTSDAPP | |
| SCHEMBL4706764 | 0.80 | BACE1 (0.60) | BACE1BACE2CTSDAPP | |
| SCHEMBL4708367 | 0.79 | BACE1 (0.59) | BACE1BACE2CTSDAPP | |
| SCHEMBL4707085 | 0.79 | BACE1 (0.59) | BACE1BACE2CTSDAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966185-A2 | 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION | Wyeth a Corporation of the State of Delaware (US) | 2008-09-10 | — | — | EP | claimed |
| US-20070191431-A1 | 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation | WYETH (US) | 2007-08-16 | — | — | US | claimed |
| WO-2007078813-A2 | 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-07-12 | — | — | WO | claimed |
| EP-1966185-A2 | 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION | Wyeth a Corporation of the State of Delaware (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070191431-A1 | 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation | WYETH (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007078813-A2 | 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191431-A1 | 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation | BACE1, BACE2, PSEN1 | BACE1 1/4885BACE2 2/4885CTSD 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.